USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Innovations in Small Molecule Drug Delivery and Formulation
Innovations in Small Molecule Drug Delivery and Formulation
Disruptive Technologies Drive Growth Opportunities for New Product Launches
19-Feb-2024
Global
Description
Small molecules, which are the leading drug class across indications, face several issues that threaten their drug delivery efficacy. They suffer from off-target effects, poor bioavailability, low solubility, systemic toxicity, and poor permeability. While the small molecule drug development pipeline remains a leading therapeutic class, it is essential to intensify R&D to improve drug delivery approaches. This Frost & Sullivan analysis of the latest advances in small molecule drug delivery covers developments in organic, inorganic, and carrier-free small molecule drug delivery systems (DDSs) as well as developments in formulations for improved patient adherence and targeted small molecule delivery.
Small molecule drug modification approaches—such as the modification of functional groups, masking undesirable chemical groups, conjugation of targeting ligands—remain a widespread method for drug delivery. However, other approaches are emerging, including prodrug strategies, small molecule-drug conjugates (SMDCs), and multivalent delivery systems, which serve to modify the drug and achieve desirable drug properties—higher solubility and bioavailability and better targeted delivery.
As advanced technology platforms for the development of novel DDSs emerge, new small molecule DDSs experience more widespread adoption. Development has accelerated for lipid-based, polymer-based, and dendrimer DDSs. These improve the sustained release and target specificity of small molecules. For instance, cancer cells are specifically targeted using improved versions of the existing delivery systems and newer delivery systems.
Emerging smart and programmable stimuli-response delivery systems are industry-disrupting technologies that can use any type of carrier for targeted and sustained small molecule drug release. Nanocarriers and nanoformulations are a key industry trend across all delivery vehicle types under development for multiple indications. Naturally derived carriers—such as exosomes and blood components—are under research for their biocompatibility and biodegradability properties. Lipid-based carriers lead in the oral formulations segment, especially for small hydrophobic molecules. Carrier-free self-assembly nanodrugs are emerging as the next generation of small molecule drugs.
These new developments and approaches in formulations help improve patient adherence. Dry powder inhalable formulations for cancer and pulmonary diseases increase the bioavailability of small molecule drugs and patient adherence, especially in comparison to injectables. Oral formulations and injectables remain one of the most widely adopted modes of administration for cancer and neurological and pulmonary diseases, while the sublingual mode is under exploration.
Table of Contents
Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on Advances in the Small Molecule Drug Delivery Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Research Methodology
Growth Drivers
Growth Driver Analysis
Growth Restraints
Growth Restraint Analysis
Scope of Analysis
Segmentation
Challenges in Small Molecule Drug Delivery
Trends in Small Molecule Drug Delivery
Introduction to Small Molecule Drug Delivery Approaches
Drug Modification Approaches That Enhance Bioavailability
Key Innovators in Drug Modification Approaches
Ligand Conjugation for an Improved Targeted Delivery
Ligand Conjugation for an Improved Targeted Delivery (continued)
Key Innovators - Ligand Conjugation
Carriers
Liposomes
Lipid NPs
Niosomes
Key Innovators in Emerging Lipid-based Organic Carriers
Polymeric Micelles
Polymeric NPs
Polymeric Microspheres
Key Innovators in Polymer Based Carriers
Lipid-polymer Hybrid NPs
Hydrogels
Dendrimers
Carbon Dots
DNA Nanobots
Key Innovators in Emerging Organic Carriers
Naturally Derived Carriers
Naturally Derived Carriers (continued)
Inorganic Carriers
Carrier-free Drugs
Emerging Platforms—Programmable DDSs
Smart Stimuli-response Systems
Nanoparticles as Carriers for DDSs
The Role of AI in Selecting Drug Delivery Vehicles and Formulations
Small Molecule Drug Delivery Formulation Systems
Small Molecule Mode of Administration and Formulations
The Role of Excipients in Formulation
Inhalable Powder Formulations
Key Innovators
LNPs in Oral Formulations
Key Innovators and Innovations in Oral Formulation and Delivery
Polymeric DDSs in Injectables
Key Innovators
Developments in Buccal/Sublingual Delivery
Small Molecule DDS Trends per Disease Area
Small Molecule DDS Trends per Disease Area (continued)
Small Molecule Drug Delivery Industry Players
Collaboration Landscape for Small Molecule DDS
Key CDMO Players Offering Advanced Drug Delivery and Formulation Platforms for Small Molecule Delivery
Key CDMO Players Offering Advanced Drug Delivery and Formulation Platforms for Small Molecule Delivery
Key CDMO Players Offering Advanced Drug Delivery and Formulation Platforms for Small Molecule Delivery
Growth Opportunity 1: Collaborating with CDMOs to Intensify R&D Activities
Growth Opportunity 1: Collaborating with CDMOs to Intensify R&D Activities (continued)
Growth Opportunity 2: Integrating AI for Advanced Drug Delivery Approaches
Growth Opportunity 2: Integrating AI for Advanced Drug Delivery Approaches (continued)
Growth Opportunity 3: Simpler Administration Modes That Increase Patient Adherence
Growth Opportunity 3: Simpler Administration Modes That Increase Patient Adherence (continued)
Technology Readiness Levels (TRL): Explanation
Your Next Steps
Why Frost, Why Now?
Legal Disclaimer
Popular Topics
| Author | Priyanka Jain |
|---|---|
| Industries | Healthcare |
| No Index | No |
| Is Prebook | No |
| Podcast | No |
| WIP Number | DAD8-01-00-00-00 |